Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design

Abstract

A successful HIV vaccine will likely induce both humoral and cell-mediated immunity, however, the enormous diversity of HIV has hampered the development of a vaccine that effectively elicits both arms of the adaptive immune response. To tackle the problem of viral diversity, T cell-based vaccine approaches have focused on two main strategies (i) increasing the breadth of vaccine-induced responses or (ii) increasing vaccine-induced responses targeting only conserved regions of the virus. The relative extent to which set-point viremia is impacted by epitope-conservation of CD8+ T cell responses elicited during early HIV-infection is unknown but has important implications for vaccine design. To address this question, we comprehensively mapped HIV-1 CD8+ T cell epitope-specificities in 23 ART-naïve individuals during early infection and computed their conservation score (CS) by three different methods (prevalence, entropy and conseq) on clade-B and group-M sequence alignments. The majority of CD8+ T cell responses were directed against variable epitopes (p<0.01). Interestingly, increasing breadth of CD8+ T cell responses specifically recognizing conserved epitopes was associated with lower set-point viremia (r = - 0.65, p = 0.009). Moreover, subjects possessing CD8+ T cells recognizing at least one conserved epitope had 1.4 log10 lower set-point viremia compared to those recognizing only variable epitopes (p = 0.021). The association between viral control and the breadth of conserved CD8+ T cell responses may be influenced by the method of CS definition and sequences used to determine conservation levels. Strikingly, targeting variable versus conserved epitopes was independent of HLA type (p = 0.215). The associations with viral control were independent of functional avidity of CD8+ T cell responses elicited during early infection. Taken together, these data suggest that the next-generation of T-cell based HIV-1 vaccines should focus on strategies that can elicit CD8+ T cell responses to multiple conserved epitopes of HIV-1.

Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection

“…We next calculated the estimated day of infection for all samples from the Ͻ365-dpi group as 20 days before the symptom onset date for symptomatic subjects or the midpoint between the last negative and first positive HIV test for those lacking symptoms (28,45). The median estimated duration of infection for the patients with less than 1 year of infection was 94 days (interquartile range [IQR], 52 to 138).…”

In silicodesign of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations

“…16 One such strategy is to design a vaccine that targets only the conserved epitopes and aims to induce a broader cross-protective immune response. 17,18 Epitopes are the smallest and most important units that can elicit immune responses. As such, they are potential candidates for modern vaccine design and have unique advantages.…”

Human Immunodeficiency Virus (HIV)

“…Subsequently, high-avidity IgG antibodies against all HIV proteins are developed, typically within 1-3 weeks. A specific T-cell response is induced against a variety of epitopes of HIV proteins [76]. …”